An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old
Latest Information Update: 28 Oct 2021
At a glance
- Drugs Enterovirus A vaccine (Primary) ; Aluminium hydroxide
- Indications Enterovirus infections
- Focus Pharmacodynamics
- Sponsors Enimmune Corporation
- 06 Aug 2019 Status changed to completed as per results published in the Vaccine
- 06 Aug 2019 Results published in the Vaccine
- 04 Sep 2017 New trial record